News/ News/ R&D Theravance axes staff as lead pipeline drug flunks phase 3 trial Phil Taylor R&D, Theravance, workforce 0 Comment Theravance has been forced to downsize its business after its lead pipeline drug ampreloxatine missed the mark in Share X Theravance axes staff as lead pipeline drug flunks phase 3 trial https://pharmaphorum.com/news/theravance-axes-staff-as-lead-pipeline-drug-flunks-phase-3-trial/
News/ US FDA rejects Sunovion’s nebulised COPD drug Richard Staines COPD, Mylan, respiratory, Sunovio, Theravance 0 Comment The US regulator has rejected Sunovion’s nebulised therapy for chronic obstructive pulmonary disease (COPD), leaving the company struggling Share X FDA rejects Sunovion’s nebulised COPD drug https://pharmaphorum.com/news/fda-rejects-sunovions-nebulised-copd-drug/
